Ovid Posts $20.8M Q3 Loss, $161.4M Cash Into 2029, Three Readouts Set for Early 2027
OVID has more than doubled off its 52-week low of $1.18 on elevated volume (3.3× avg).
Summary
Ovid ended Q3 2026 with $161.4 million in cash and a runway into 2029, funding a widened $20.8 million quarterly loss while three clinical readouts approach in early 2027.
Key Events · Earnings and Guidance · OVID
-
Q3 Loss Widens on Clinical Spend
Net loss was $20.8 million, or $0.10 per share, versus $12.2 million ($0.17 per share) a year earlier; R&D rose to $15.7 million from $5.9 million on OV329 and OV4071 study activity.
-
Cash Runway Extended Into 2029
Cash, cash equivalents and marketable securities totaled $161.4 million at September 30, 2026, up from $90.4 million at December 31, 2025, funding operations into 2029.
-
Three Readouts Set for Early 2027
OV329 photosensitivity topline is expected in Q1 2027, alongside OV4071 Phase 1 topline and the translational ketamine challenge study; the OV329 Phase 2 focal epilepsy study reads out in H2 2027.
-
Pediatric TSC Study Before Year-End
Ovid plans to initiate a study of its pediatric OV329 formulation in TSC-associated seizures in Q4 2026, the first indication in a broader developmental epileptic encephalopathy plan.
Analysis · OVID · Life Sciences
Cash is the headline this quarter: $161.4 million at September 30 extends the runway into 2029, so Ovid does not need to raise money before its near-term data lands. That matters because spending is accelerating — R&D jumped to $15.7 million from $5.9 million a year ago as the OV329 and OV4071 programs move through the clinic — and the loss widened to $20.8 million from $12.2 million. The pipeline calendar is now concrete: OV329 photosensitivity data and OV4071 Phase 1 plus ketamine-challenge results in Q1 2027, the OV329 Phase 2 focal epilepsy readout in H2 2027, and a pediatric TSC study starting before year-end 2026. The soticlestat interest, worth up to $294.5 million in milestones plus low- to mid-single-digit royalties, remains an off-balance-sheet option rather than cash in hand.
How filings like this one have moved
In the 30 days to Nov 10, 2026, 36.4% of the 3168 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, OVID was trading at $2.75 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $556.6M. The 52-week trading range was $1.18 to $3.11. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.